Pharmacology of Sleep



I have no disclosures, affiliations, nor conflict in interest financial or otherwise in relation to this presentation.







Objectives

- Identify criteria for sleep disorders requiring pharmacological management
- Discuss pharmacological treatment for sleep disorders
- Recognize when a child should be referred to sleep center




Why Sleep?

- Not 100% sure?
- Critical for Growth and Development
- Important for Healthy Immune Response
- Foundation for Recovery and Normal Body Function



How much sleep is enough?

Hours





To know sleep is to know the brain

- Neurobiology is still an evolving field
- Very complex circuits with multiple inputs in vast network of connections




Quick Review!

- Conceptualize as "Lock and Key"
- Agonist => Forward Key
- Antagonist =>Blocks Key
- Inverse Agonist => Emergency Shutdown/Lock breaks
- Competitive vs Non-competitive
- Partial=>Reduced effect



Competitive Agonist











Competitive Partial Agonist











Competitive Antagonist





Competitive Inverse Agonist











Non-Competitive Agonist





What makes us sleep?





Adenosine

- Created from used ATP aka ENERGY
- Builds up throughout the day
- Caffeine is a competitive antagonist

 Note to self: Slowly consume caffeine throughout the day to <u>STAY</u> alert.



Melatonin

- Made in your pineal gland
- Circadian rhythm "Body's Natural Clock" in Suprachiasmatic Nucleus
- Positive feedback loop
- Blocked by bright lights (especially blue?)





Sleep-Wake Signals

Two main circuits:

Off/Sleep Promoter (GABA, Melatonin)

On/Wake Promoter (Histamine, Orexin)



HERE WE GO!




Insomnia

- Difficulty falling, maintaining, or getting back to sleep
- Impacts life
- >3 months duration



Insomnia is Multifactorial





When to start pharmacologic therapy

- QoL Burden
- Ability to implement non-pharmacologic interventions
- Adjunctive to non-pharmacologic intervention



Why should we avoid sleep medicines?

- No pediatric FDA approved sleep aid for insomnia
 - Only doxepin, benzos, Z-drugs, melatonin agonists, new orexin antagonists
- Band-aid, not building skills
- Side Effects
- Nearly all sleep aids cause habituation/tolerance
- Withdrawal



Supplemental Melatonin

- FDA Supplement, not Medicine
 - Studies have shown actual mg values vary greatly
- Often mixed with other supplements
 - St. John's Wort
 - Valerian root
 - GABA
 - L-Tryptophan
 - Magnesium
 - Herbal Extracts
 - Tart Cherry Juice



Supplemental Melatonin

- Jump starts endogenous melatonin positive feedback loop
- No tolerance, no withdrawal, etc!
- Very poor bioavailability ~15% (first pass effect)
- Quickly metabolized 15-45 minutes
 - XR formulation ~1.5-2 hours
- Parasomnias, nightmares, hangover effect, irritability, very low risk of seizure, headaches



Irritability with Sleep Medications

- Disinhibition of frontal lobe and executive functioning skills
 - "Tipsy but not passed out"
 - Increased sleep fighting/negative behaviors
- Often due to patient brain's receptor profile and reaction to medication



Most Drugs are not Precise

Drugs hit multiple receptors

 Drugs have different affinities to different receptors even if they are in the same "class"


 Patients have different responses to the same medication





Antipsychotics

- Sedative effect driven by Histamine-1, Muscarinic-1, adrenergic- α 1 antagonism in the brain
- Ultimate sledgehammer











Using sleep medications

- Sedation goal (Sleep Onset or Maintenance)
- Treat other underlying issues



Quetiapine (Seroquel)

- Half life = 6-7 hours
- Time peak=2 hours for IR, 5 hours for XR
- LOW DOSE (25-100 mg)
- Weight gain, HLD, Fatty Liver, Diabetes, Dizziness, Dry Mouth, Nausea/Vomiting
- Baseline and 6 months monitoring of Glucose, HgA1c, Lipids, and CMP
- Off-label for refractive Anxiety/ADHD
- Medium Habituation Speed
- Both for sleep onset and maintenance



Trazodone

- Serotonin 2 Antagonist/Reuptake Inhibitor
- Low Dose for Sleep (12.5-100 mg)
- Antidepressant
- Biphasic Half-life (3-6 hrs, then 5-9 hrs)
- Nausea, vomiting, blurred vision, constipation, dry mouth, dizziness, tremor, rash, easy bleeding
- Quick Habituation, Used best as PRN
- Both sleep onset and maintenance



Diphenhydramine (Benadryl)

- First Generation Anti-Histamine
- Half-Life (2-7 Hrs), Peak 2 hours
- High Habituation Rate
- Paradoxical effect, dizziness, constipation, blurred vision, dry mouth, irregular heartbeat, seizures
- Sleep onset only



Hydroxyzine

- Antihistamine
- Half-life 7 hours (in kids), peak 0.5-2 hrs
- Dose: 10-25 mg
- Dry mouth, blurred vision, urinary retention, constipation, tremor, headache, rash
- Fast Habituation, Use PRN
- Sleep onset only



Clonidine IR

- Alpha 2 agonist
- Half-life 5-13 hrs, Peak 1-3 hours
- Dose 0.03-0.4 mg
- HTN, ADHD, ODD
- Dry mouth, constipation, dizziness, irregular heartbeat, hypotension, nausea, vomiting
- Average Habituation Rate
- Sleep onset only



Clonidine XR

- Now in capsule (Kapvay) and liquid beads (Onyda XR)
- Patches rarely effective from a sleep standpoint
- Half-life 5-13 hrs, Peak 7-8 hours
- Sleep maintenance

Can combine Clonidine XR + Clonidine IR



Gabapentin (Neurontin)

- Alpha 2 delta ligand calcium channel agonist
 - Thought to regulate dopamine indirectly
- 2-5 mg/kg QHS for Restless Leg Syndrome/Periodic Limb Movement Disorder
- Half-Life 5-7 hrs, Peak 2-3 Hrs (RENAL EXCRETION)
- Dizziness, ataxia, blurred vision, vomiting, GERD, emotional lability
- Habituation less likely if used only once a day
- Sleep maintenance primarily



Mirtazapine (Remeron)

- Dual serotonin & norepinephrine agent
- Lower doses 7.5 mg, 15 mg
- Half-life 20-40 hrs, peak time 2 hours

- Weight gain, worsened restlessness, rarely seizures
- Anxiety, Depression
- Sleep onset and maintenance



Doxepin (Silenor)

- Tricyclic Antidepressant
- Almost solely H1 antagonist at low doses
- Dose 3-10 mg, liquid formulation is generic
- Half life 8-15 hours, Peak 2 hours
- Side effects rare at low doses! Dry mouth, constipation, blurred vision
- Sleep maintenance only



Clonazepam

- Benzodiazepine (GABA Agonist)
- Half life 30 hours, Peak 1-4 hours
- Used primarily for parasomnias in extreme cases
- Can lead to addiction
- Respiratory depression, dizziness, cognitive slowing, hallucinations, dry mouth
- Sleep onset and maintenance



Eszopiclone (Lunesta), Zolpidem (Ambien), Zaleplon (Sonata)

- Non-benzodiazepine benzodiazepine receptor non-competitive agonist
- Half-life ½ as short as adults
 - Sonata ~30 minutes, Ambien 1-2 hours, Lunesta ~4 hours
- Peak times
 - Sonata 10 minutes, Ambien 1 hour, Lunesta 2 hours
- Parasomnias, amnesia, dizziness, hallucinations, headache, abdominal pain, nausea, irritability, infection risk
- Sleep onset only in children



How much is significant?

- Zolpidem
 - Improves sleep onset by 20-30 minutes
 - Improves total sleep time by 20-30 minutes
 - Improves sleep efficiency by 4-5%
- Patients report falling asleep faster, more refreshed, waking up much less than placebo
 - Amnesia?




Restless Leg Syndrome

- Urge to move legs, unpleasant sensation in legs
- Begins or worsens during periods of rest
- Partially or totally relieved by movement
- Only during periods of rest or inactivity, worse in the evening
- Diagnosis strengthened by first degree relative with RLS or Periodic Limb Movements of Sleep on sleep study
- Associated with Dopamine!



Periodic Limb Movements of Sleep





Iron


- Iron co-factor for tyrosine hydroxylase (rate limiting step of release of dopamine)
- Serum iron levels poorly correlate with CSF
- For Restlessness, Ferritin > 75 ng/ml
- Avoid dairy
- 2 mg/kg elemental iron daily orally
- May consider IV iron infusion
- Closely regulated by body



Sleep Studies

- Done at Night from 8p-6a, Sun-Fri
- Akron & Mahoning Valley/Boardman Locations
- 2-4 month wait
- Results available ~2 weeks after test







Sleep Clinic or Sleep Study

- Sleep study for Sleep Apnea or Restless Sleep
 - Snoring + 1
 - Witnessed apneas
 - Hypersomnia
 - Sleep disruption
 - Large Tonsils
 - Obese
 - "Wild" Sleeper, Sheets/Blankets tossed about in AM



Sleep Clinic

- Insomnia
- Circadian Rhythm Disorders
- PAP management
- Parasomnias
- Hypersomnia/Excessive Daytime Sleepiness
- Sleep Training



Contact

ddrees@akronchildrens.org



References

- 1. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline PubMed. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 02/15/2017;13(2)
- 2. Stahl SM. Prescriber's Guide Children and Adolescents: Stahl's Essential Psychopharmacology. vol 1. Cambridge University Press; 2018.
- 3. Stahl SM, Jones PM. Prescriber's Guide in Psychiatry. Cambridge University Press; 2024.
- 4. Stahl SM. Stahl's Essential Psychopharmacology. vol 4. Cambridge University Press. 2013.
- 5. European expert guidance on management of sleep onset insomnia and melatonin use in typically developing children PubMed. European journal of pediatrics. 2024 Jul;183(7)
- 6. Khan FH, Ahlberg CD, Chow CA, Shah DR, Koo BB. Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome. J Neurol. 2017 Aug;264(8):1634-1641.
- 7. Simakajornboon N, Kheirandish-Gozal L, Gozal D. Diagnosis and management of restless legs syndrome in children. Sleep Med Rev. 2009 Apr;13(2):149-56.
- 8. Koo, Brian. (2015). Restless Legs Syndrome: Would You Like That with Movements or Without?. Tremor and other hyperkinetic movements (New York, N.Y.). 5. 316. 10.7916/D80P0Z0H.
- 9. Allen RP, Picchietti DL, et al; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance. Sleep Med. 2014 Aug;15(8):860-73.
- 10. Herrmann WM, et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res. 1993 Nov-Dec;21(6):306-22.
- 11. Reichert CF, Deboer T, Landolt HP. Adenosine, caffeine, and sleep-wake regulation: state of the science and perspectives. J Sleep Res. 2022 Aug;31(4):e13597.
- 12. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994 May;55(5):192-9.
- 13. Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012 Nov 1;35(11):1551-7.
- 14. Jones R, Rickards H, Cavanna AE. Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis. 2010 Nov 23;2:45-55. doi: 10.4137/JCNSD.S4886. PMID: 23861631: PMCID: PMC3661230.
- 15. Green, Amit & Sher, Simona & Khatib, Soliman & Dagan, Yaron. (2020). The Possible Role of Endozepines in Sleep Regulation and Biomarker of Process S of the Borbély Sleep Model. Chronobiology International. 38. 10.1080/07420528.2020.1849252.

